Published in Appl Environ Microbiol on April 19, 2013
Bioengineering Lantibiotics for Therapeutic Success. Front Microbiol (2015) 0.86
Variable characteristics of bacteriocin-producing Streptococcus salivarius strains isolated from Malaysian subjects. PLoS One (2014) 0.85
The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics. Microbiologyopen (2014) 0.79
Biosynthesis and transport of the lantibiotic mutacin 1140 produced by Streptococcus mutans. J Bacteriol (2015) 0.77
Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical production. Microb Cell Fact (2016) 0.76
Two flavoenzymes catalyze the post-translational generation of 5-chlorotryptophan and 2-aminovinyl-cysteine during NAI-107 biosynthesis. ACS Chem Biol (2016) 0.75
Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes. Chem Rev (2017) 0.75
Draft Genome Sequence of Oral Bacterium Streptococcus mutans JH1140. Genome Announc (2016) 0.75
Advances in the Microbiome: Applications to Clostridium difficile Infection. J Clin Med (2016) 0.75
Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery. Appl Environ Microbiol (2017) 0.75
Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci U S A (2002) 8.25
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Novel shuttle plasmid vehicles for Escherichia-Streptococcus transgeneric cloning. Gene (1983) 5.30
Subtilases: the superfamily of subtilisin-like serine proteases. Protein Sci (1997) 4.86
Biosynthesis and mode of action of lantibiotics. Chem Rev (2005) 4.59
A quorum-sensing signaling system essential for genetic competence in Streptococcus mutans is involved in biofilm formation. J Bacteriol (2002) 3.55
An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science (2006) 3.05
Asparagine-mediated self-association of a model transmembrane helix. Nat Struct Biol (2000) 2.97
Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol (2009) 2.56
Polar residues drive association of polyleucine transmembrane helices. Proc Natl Acad Sci U S A (2001) 2.47
The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol (2004) 2.36
Induction of nonbilayer structures in diacylphosphatidylcholine model membranes by transmembrane alpha-helical peptides: importance of hydrophobic mismatch and proposed role of tryptophans. Biochemistry (1996) 2.31
Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J Biol Chem (2003) 2.26
The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. Proc Natl Acad Sci U S A (2004) 2.04
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol (2010) 1.82
Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Environ Microbiol (1999) 1.66
The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol (2008) 1.62
Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun (1984) 1.48
Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun (1998) 1.46
Production of dehydroamino acid-containing peptides by Lactococcus lactis. Appl Environ Microbiol (2007) 1.36
Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. Antimicrob Agents Chemother (2006) 1.36
Oxidative decarboxylation of peptides catalyzed by flavoprotein EpiD. Determination of substrate specificity using peptide libraries and neutral loss mass spectrometry. J Biol Chem (1995) 1.32
Mapping of a cloned glucosyltransferase gene in Streptococcus mutans. Infect Immun (1985) 1.21
Genetically modified Streptococcus mutans for the prevention of dental caries. Antonie Van Leeuwenhoek (2002) 1.21
Isolation and characterization of genetically engineered gallidermin and epidermin analogs. Appl Environ Microbiol (1995) 1.19
Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry (2008) 1.13
Lantibiotics--unusually modified bacteriocin-like peptides from gram-positive bacteria. Zentralbl Bakteriol (1993) 1.05
Structure-activity relationships in the peptide antibiotic nisin: role of dehydroalanine 5. Appl Environ Microbiol (1996) 1.04
Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. Eur J Biochem (2000) 0.99
Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect Immun (2000) 0.97
Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr Opin Microbiol (2008) 0.95
Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci (2010) 0.87
Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents (2008) 0.85
Oxidation of lanthionines renders the lantibiotic nisin inactive. Appl Environ Microbiol (2008) 0.84
Rapid method for extracting the antibiotic mutacin 1140 from complex fermentation medium yeast extract. Can J Microbiol (2009) 0.84
Structure and dynamics of the lantibiotic mutacin 1140. Biochemistry (2003) 0.82
Methodologies and strategies for the bioengineering of lantibiotics. Curr Pharm Biotechnol (2011) 0.81
Commercial development and application of type A lantibiotics. Recent Pat Antiinfect Drug Discov (2011) 0.80
Optimization of the Production of the Lantibiotic Mutacin 1140 in Minimal Media. Process Biochem (2010) 0.79
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients. Infect Immun (2003) 2.69
In vitro and in vivo studies on thermistor-based intracoronary temperature measurements: effect of pressure and flow. Catheter Cardiovasc Interv (2009) 2.04
Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One (2010) 1.87
Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc Natl Acad Sci U S A (2003) 1.60
Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog (2013) 1.55
Coronary thermodilution to assess flow reserve: validation in humans. Circulation (2002) 1.20
Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry (2008) 1.13
Identification of Candida albicans genes induced during thrush offers insight into pathogenesis. Mol Microbiol (2003) 1.13
In vivo induced antigen technology (IVIAT). Cell Microbiol (2005) 1.11
Microarray analysis of quorum-sensing-regulated genes in Porphyromonas gingivalis. Infect Immun (2005) 1.11
Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol (2011) 1.08
Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection. Infect Immun (2005) 1.04
Binding of SycH chaperone to YscM1 and YscM2 activates effector yop expression in Yersinia enterocolitica. J Bacteriol (2004) 1.03
Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans. Biochemistry (2009) 1.01
Impassable YscP substrates and their impact on the Yersinia enterocolitica type III secretion pathway. J Bacteriol (2008) 1.01
Muricholic acids inhibit Clostridium difficile spore germination and growth. PLoS One (2013) 0.98
Identification of group A Streptococcus antigenic determinants upregulated in vivo. Infect Immun (2005) 0.95
Biosynthesis of an antifungal oligopeptide in Burkholderia contaminans strain MS14. Biochem Biophys Res Commun (2009) 0.93
Genetic and biochemical map for the biosynthesis of occidiofungin, an antifungal produced by Burkholderia contaminans strain MS14. Appl Environ Microbiol (2011) 0.93
Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis. PLoS One (2008) 0.93
Yersinia enterocolitica type III secretion of YopR requires a structure in its mRNA. Mol Microbiol (2008) 0.92
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother (2012) 0.92
AmbR1 is a key transcriptional regulator for production of antifungal activity of Burkholderia contaminans strain MS14. FEMS Microbiol Lett (2009) 0.91
Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria. Proc Natl Acad Sci U S A (2013) 0.91
Occidiofungin's chemical stability and in vitro potency against Candida species. Antimicrob Agents Chemother (2011) 0.90
Identification and testing of Porphyromonas gingivalis virulence genes with a pPGIVET system. Infect Immun (2002) 0.90
IA3, an aspartic proteinase inhibitor from Saccharomyces cerevisiae, is intrinsically unstructured in solution. Biochemistry (2004) 0.88
In vivo induced antigenic determinants of Actinobacillus actinomycetemcomitans. FEMS Microbiol Lett (2004) 0.87
Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci (2010) 0.87
Identification of genes expressed in cultures of E. coli lysogens carrying the Shiga toxin-encoding prophage Φ24B. BMC Microbiol (2012) 0.86
The secretion signal of YopN, a regulatory protein of the Yersinia enterocolitica type III secretion pathway. J Bacteriol (2004) 0.86
Genes of periodontopathogens expressed during human disease. Ann Periodontol (2002) 0.85
Oxidation of lanthionines renders the lantibiotic nisin inactive. Appl Environ Microbiol (2008) 0.84
Rapid method for extracting the antibiotic mutacin 1140 from complex fermentation medium yeast extract. Can J Microbiol (2009) 0.84
In vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT). Infect Disord Drug Targets (2006) 0.82
Commercial development and application of type A lantibiotics. Recent Pat Antiinfect Drug Discov (2011) 0.80
Nonclinical toxicological evaluation of occidiofungin, a unique glycolipopeptide antifungal. Int J Toxicol (2012) 0.79
The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics. Microbiologyopen (2014) 0.79
In vivo induced genes in human diseases. Periodontol 2000 (2005) 0.78
Multipronged approach for engineering novel peptide analogues of existing lantibiotics. Expert Opin Drug Discov (2015) 0.78
Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. Eur J Pharm Sci (2010) 0.77
The Burkholderia contaminans MS14 ocfC gene encodes a xylosyltransferase for production of the antifungal occidiofungin. Appl Environ Microbiol (2013) 0.77
The antifungal occidiofungin triggers an apoptotic mechanism of cell death in yeast. J Nat Prod (2013) 0.76
In vivo expression of bacterial genes during human infections. Methods Mol Med (2003) 0.76
The presence of two cyclase thioesterases expands the conformational freedom of the cyclic Peptide occidiofungin. J Nat Prod (2013) 0.75
Arterial age as a function of coronary artery calcium. Am J Cardiol (2009) 0.75
Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. J Pharm Biomed Anal (2008) 0.75